Federated Hermes Inc. Raises Stake in Vaxcyte, Inc. $PCVX

Federated Hermes Inc. lifted its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 6,856.3% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 18,156 shares of the company’s stock after buying an additional 17,895 shares during the quarter. Federated Hermes Inc.’s holdings in Vaxcyte were worth $654,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. CWM LLC raised its holdings in Vaxcyte by 197.3% in the 2nd quarter. CWM LLC now owns 1,680 shares of the company’s stock valued at $55,000 after acquiring an additional 1,115 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of Vaxcyte by 176.7% during the 2nd quarter. Blue Trust Inc. now owns 2,161 shares of the company’s stock worth $70,000 after acquiring an additional 1,380 shares during the period. Virtus Investment Advisers LLC boosted its position in shares of Vaxcyte by 45.8% in the second quarter. Virtus Investment Advisers LLC now owns 2,729 shares of the company’s stock worth $89,000 after acquiring an additional 857 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in Vaxcyte by 96.3% in the third quarter. Nisa Investment Advisors LLC now owns 3,254 shares of the company’s stock valued at $117,000 after purchasing an additional 1,596 shares during the period. Finally, J.Safra Asset Management Corp increased its position in Vaxcyte by 18.5% during the second quarter. J.Safra Asset Management Corp now owns 3,746 shares of the company’s stock worth $122,000 after purchasing an additional 585 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Insiders Place Their Bets

In other Vaxcyte news, insider Harpreet S. Dhaliwal sold 9,743 shares of the business’s stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $46.69, for a total transaction of $454,900.67. Following the completion of the sale, the insider owned 23,928 shares in the company, valued at $1,117,198.32. The trade was a 28.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Elvia Cowan sold 11,623 shares of the firm’s stock in a transaction dated Tuesday, December 23rd. The stock was sold at an average price of $47.92, for a total transaction of $556,974.16. Following the completion of the transaction, the senior vice president owned 14,534 shares in the company, valued at approximately $696,469.28. The trade was a 44.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 3.10% of the company’s stock.

Wall Street Analysts Forecast Growth

PCVX has been the topic of a number of research analyst reports. Needham & Company LLC lifted their target price on Vaxcyte from $90.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Leerink Partners set a $77.00 price target on Vaxcyte and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. BTIG Research restated a “buy” rating and set a $85.00 target price on shares of Vaxcyte in a research note on Monday, November 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Friday, January 9th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $116.00 target price on shares of Vaxcyte in a research report on Monday, February 2nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Vaxcyte has an average rating of “Moderate Buy” and a consensus price target of $93.83.

Vaxcyte Trading Up 4.2%

Shares of PCVX opened at $56.15 on Friday. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $90.47. The firm has a market cap of $7.35 billion, a price-to-earnings ratio of -11.60 and a beta of 1.33. The stock has a 50 day moving average of $48.04 and a 200-day moving average of $41.51.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.